Spanish plasma-derived medicines specialist Grifols (MCE: GRF) announced that the positive Phase III study data on its fibrinogen concentrate, BT524, has been published in eClinicalMedicine, a ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

Grifols, S.A. (NASDAQ:GRFS) is a company that unfortunately has not been performing as I expected it to. My position is in the green, but this has more to do with FX and me adding shares below my ...

I have been covering Grifols (NASDAQ:GRFS) for some time now, through the potential of a sale of the entire company, and back again when that sale did not materialize. I view this as a very good ...

(Bloomberg) -- Grifols SA, the Spanish pharmaceutical company hit by a short seller attack this year, said it overstated the value of its stake in a Chinese firm and reported an accounting ...

Grifols (GRFS) said: “Grifols remains focused on the continued execution of its strategic plan and reaffirms its guidance for FY2025.Due to the impact of the Inflation Reduction Act on its ...

Grifols GRF-0.39%decrease; red down pointing triangle said it plans to outline its strategy as a standalone company after Brookfield Asset Management dropped out of talks for a 6.45 billion-euro ...

The Grifols family has held "very preliminary talks" through several investment firms over a potential takeover bid, according to a source close to the pharmaceutical company's reference shareholders.

Spanish drugmaker Grifols SA, the target of a short-seller attack earlier in the year, is seeking to hire an external consultancy firm to help deal with minority investors as it faces a takeover ...

Wolfspeed bankruptcy watch, North Carolina lands more data centers, Duke University’s funding crunch, and an AI companion named Frank. But first, NC high schools rethink career readiness.